Monoclonal antibodies lock down SARS-CoV-2 spike

Trends Immunol. 2023 Oct 5:S1471-4906(23)00202-8. doi: 10.1016/j.it.2023.09.006. Online ahead of print.ABSTRACTSARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective. Liu et al. unveil potent human mAbs that neutralize all tested SARS-CoV-2 variants by locking the Spike protein RBD in a downward conformation, thus inhibiting receptor engagement.PMID:37805348 | DOI:10.1016/j.it.2023.09.006

Source: Trends in Immunology - October 7, 2023 Category: Allergy & Immunology Authors: Hsiang-Chi Huang Davide Angeletti Source Type: research